Amylyx Pharmaceuticals Q4 2022 Earnings Report $3.60 +0.10 (+2.86%) As of 01/17/2025 04:00 PM Eastern Earnings HistoryForecast Amylyx Pharmaceuticals EPS ResultsActual EPS-$0.65Consensus EPS -$0.77Beat/MissBeat by +$0.12One Year Ago EPSN/AAmylyx Pharmaceuticals Revenue ResultsActual Revenue$21.89 millionExpected Revenue$3.05 millionBeat/MissBeat by +$18.84 millionYoY Revenue GrowthN/AAmylyx Pharmaceuticals Announcement DetailsQuarterQ4 2022Date3/13/2023TimeAfter Market ClosesConference Call ResourcesConference CallConference Call TranscriptPress ReleaseAMLX Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by Amylyx Pharmaceuticals Earnings HeadlinesAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives $7.33 Average PT from BrokeragesJanuary 18 at 1:55 AM | americanbankingnews.comAmylyx Pharmaceuticals Enters Underwriting Agreement for Public OfferingJanuary 13, 2025 | americanbankingnews.comWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in this sector.January 18, 2025 | Behind the Markets (Ad)Amylyx announces common stock offering, no amount givenJanuary 10, 2025 | markets.businessinsider.comAmylyx stock dips after pricing $60M stock offeringJanuary 10, 2025 | seekingalpha.comAmylyx Pharmaceuticals Prices Offering Of Approx. 17.1 Mln Shares At $3.50 Per ShareJanuary 10, 2025 | markets.businessinsider.comSee More Amylyx Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Amylyx Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Amylyx Pharmaceuticals and other key companies, straight to your email. Email Address About Amylyx PharmaceuticalsAmylyx Pharmaceuticals (NASDAQ:AMLX), a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.View Amylyx Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Amazon’s Next Earnings Could Trigger a Stock BreakoutS&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead? Upcoming Earnings Interactive Brokers Group (1/21/2025)Netflix (1/21/2025)Capital One Financial (1/21/2025)HDFC Bank (1/21/2025)3M (1/21/2025)Prologis (1/21/2025)Charles Schwab (1/21/2025)Abbott Laboratories (1/22/2025)Ameriprise Financial (1/22/2025)Amphenol (1/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
